Abstract

Central nervous system (CNS) disorders especially neurodegenerative disorders are the major challenge for public health and demand the great attention of researchers to protect people against them. In past few decades, different treatment strategies have been adopted, but their therapeutic efficacy are not enough and have only shown partial mitigation of symptoms. Blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BSCFB) guard the CNS from harmful substances and pose as the major challenges in delivering drugs into CNS for treatment of CNS complications such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), stroke, epilepsy, brain tumors, multiple sclerosis (MS), and encephalitis, etc. Nanotechnology has come out as an exciting and promising new platform of treating neurological disorders and has shown great potential to overcome problems related to the conventional treatment approaches. Molecules can be nanoengineered to carry out multiple specific functions such as to cross the BBB, target specific cell or signaling pathway, respond to endogenous stimuli, and act as a vehicle for gene delivery, support nerve regeneration and cell survival. In present review, the role of nanocarrier systems such as liposomes, micelles, solid lipid nanoparticles (SLNPs), dendrimers, and nanoemulsions for delivery of various neurotherapeutic agents has been discussed, besides this, their mechanism of action, and nanoformulation of different neuroprotective agents like curcumin, edaravone, nerve growth factors in CNS disorders like Alzheimer’s, Parkinsonism, epilepsy, stroke, and brain tumors has been reviewed.

Highlights

  • Central nervous system (CNS) disease and disorders are posing great challenge for mankind and is the fastest growing area appealing for the attention of researchers

  • We provide an overview of different nanoformulations of neuroprotective agents, with particular emphasis on their usefulness in different neurological diseases and the opportunities for future research

  • The results demonstrated the higher uptake of drug when it was encapsulated in SLNs (Manjunath and Venkateswarlu, 2006)

Read more

Summary

Introduction

Central nervous system (CNS) disease and disorders are posing great challenge for mankind and is the fastest growing area appealing for the attention of researchers. Immunoliposomes as nanocarrier systems for brain drug delivery have some usage in gene therapy as demonstrated by TRsMAbs-targeted liposome conjugated with a plasmid for tyrosine hydroxylase in treating PD in a rat model (Zou et al, 2010).

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call